​Preclinical Stage Partnering Terms and Agreements 2010-2015 is a new market research publication announced by Reportstack. This report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter preclinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest preclinical agreements announced in the healthcare sector.

This report contains a comprehensive listing of all preclinical stage partnering deals announced since 2010 including financial terms where available including over 2,000 links to online deal records of actual preclinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

To access full report with TOC, please visit ​Preclinical Stage Partnering Terms and Agreements 2010-2015.

The initial chapters of this report provide an orientation of preclinical stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner preclinical stage compounds/products.

Chapter 3 provides an overview of preclinical stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in preclinical stage deals.

Chapter 5 provides a review of trends in preclinical stage deal making since 2010. Deals are listed by big pharma and big biotech dealmaking in preclinical stage, deal type, therapy type and technology type.

Chapter 6 provides a detailed analysis of preclinical stage payment terms including average headline, upfront, milestone and royalty rates for preclinical deals.

Chapter 7 provides a review of the leading preclinical stage deal by headline value.

Chapter 8 provides a comprehensive listing of the top 50 big pharma and top 50 big biotech companies with a brief summary followed by a comprehensive listing of preclinical stage deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 9 provides a comprehensive and detailed review of preclinical stage partnering deals signed and announced since 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 10 provides a comprehensive directory of preclinical stage partnering deals since 2010 organized by stage of development – preclinical.

The report also includes numerous tables and figures that illustrate the trends and activities in preclinical stage partnering and deal making since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of preclinical stage products and compounds.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

​Reportstack Market Research

###